Old gout drug could help hearts of people with type 1 diabetes
NCT ID NCT05949281
First seen Jun 26, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This phase 2 trial tests whether a daily low dose of colchicine, an anti-inflammatory drug used for gout, can reduce inflammation and heart disease risk in adults with type 1 diabetes. 102 participants aged 35–80 will take either colchicine or a placebo for 26 weeks, with an optional 26-week extension and 5-year follow-up. The main goal is to see if colchicine lowers a key blood marker of inflammation (hsCRP).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- colchicine (0.5 mg oral tablet daily)
- What this could lead to
- If it works, this could point toward a way to lower heart disease risk in people with type 1 diabetes by reducing chronic inflammation.
- What could go wrong
- This is a small, early-phase trial testing only a marker of inflammation, not actual heart attacks or strokes. The drug may not show meaningful benefit or could cause side effects like stomach upset.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTERIOSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region, 2900, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can better healthcare access save hearts after prison?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- Could a simple health chat slash heart disease and cancer risk?
- Can an app and cash rewards tame type 1 diabetes in young adults?
- One scan, many answers: can a new CT predict heart risks after stenting?
- Digital coaching aims to boost heart health in obesity